Andijan Pharma Zone: What Indian Manufacturers Need to Know

Andijon-Farm was created under an intergovernmental framework specifically to host Indian pharmaceutical and biopharmaceutical manufacturers. It is established for a 30-year term with the possibility of extension, and operates under special tax and customs regimes for residents.

Eligible activities include finished pharmaceutical products, processing of medicinal plant raw materials, medical devices and equipment, and auxiliary and packaging materials.

Uzbekistan’s stated ambition is to lift national pharmaceutical output from around $620 million toward $10 billion by 2035, with Indian generics manufacturers as core partners. Reported incentives include multi-year tax exemptions inside dedicated pharma zones, subsidised land, customs-duty waivers, infrastructure support and R&D-linked incentives.

Entry begins with a feasibility and product-portfolio review: which molecules, which dosage forms, domestic market versus CIS export. The Council’s market-entry team prepares this with the investor.

Company registration inside the zone, resident status, land allocation and utility connections follow — handled through the Council’s one-window regulatory service in coordination with the zone administration.

Product registration, GMP alignment and UzStandard certification complete the path to launch, with technical translation of dossiers into Russian and Uzbek by pharmaceutical specialists.